Bibliographic Details
| Title: |
Excess Mortality in Aspirin and Dipyrone (Metamizole) Co‐Medicated Patients With Cardiovascular Disease: A Nationwide Study |
| Authors: |
Amin Polzin, Lisa Dannenberg, Carolin Helten, Martin Pöhl, Daniel Metzen, Philipp Mourikis, Christof Dücker, Ursula Marschall, Helmut L’Hoest, Beata Hennig, Saif Zako, Kajetan Trojovsky, Tobias Petzold, Christian Jung, Bodo Levkau, Tobias Zeus, Karsten Schrör, Thomas Hohlfeld, Malte Kelm |
| Source: |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 22 (2021) |
| Publisher Information: |
Wiley, 2021. |
| Publication Year: |
2021 |
| Collection: |
LCC:Diseases of the circulatory (Cardiovascular) system |
| Subject Terms: |
aggregation, aspirin, co‐medication, dipyrone, platelet activation, platelet inhibition, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| More Details: |
Background Pain is a major issue in our aging society. Dipyrone (metamizole) is one of the most frequently used analgesics. Additionally, it has been shown to impair pharmacodynamic response to aspirin as measured by platelet function tests. However, it is not known how this laboratory effect translates to clinical outcome. Methods and Results We conducted a nationwide analysis of a health insurance database in Germany comprising 9.2 million patients. All patients with a cardiovascular event in 2014 and subsequent secondary prevention with aspirin were followed up for 36 months. Inverse probability of treatment weighting analysis was conducted to investigate the rate of mortality, myocardial infarction, and stroke/transient ischemic attack between patients on aspirin‐dipyrone co‐medication compared with aspirin‐alone medication. Permanent aspirin‐alone medication was given to 26,200 patients, and 5946 patients received aspirin–dipyrone co‐medication. In the inverse probability of treatment weighted sample, excess mortality in aspirin–dipyrone co‐medicated patients was observed (15.6% in aspirin‐only group versus 24.4% in the co‐medicated group, hazard ratio [HR], 1.66 [95% CI, 1.56–1.76], P |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2047-9980 |
| Relation: |
https://doaj.org/toc/2047-9980 |
| DOI: |
10.1161/JAHA.121.022299 |
| Access URL: |
https://doaj.org/article/46863831286544e9afcf8e597f1baae2 |
| Accession Number: |
edsdoj.46863831286544e9afcf8e597f1baae2 |
| Database: |
Directory of Open Access Journals |
